OncoMatch/Clinical Trials/NCT06641635
Moderated Hypofractionated Online Adaptive Radiotherapy in Cervical Cancer
Is NCT06641635 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Moderated hypofractionated online adaptive radiotherapy and Conventional radiotherapy for cervical cancer.
Treatment: Moderated hypofractionated online adaptive radiotherapy · Conventional radiotherapy — The most common external beam radiotherapy fractionation scheme for cervical cancer is 45-50.4 Gy delivered in 25-28 fractions. However, prolonged treatment duration can lead to insufficient availability of medical resources. We hope to assess the safety and efficacy of moderated hypofractionated online adaptive radiotherapy in combination with brachytherapy in patients with cervical cancer in a multicenter study.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Disease stage
Required: Stage IB, IIA, IIB, IIIA, IIIB, IIIC1
Excluded: Stage IA, IIIC2, IVA, IVB
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: surgery
Exception: pelvic lymphadenectomy or pelvic lymph node dissection, or cervical conization
Patients who have undergone cervical cancer surgery, excluding pelvic lymphadenectomy or pelvic lymph node dissection, or cervical conization
Cannot have received: abdominal or pelvic radiotherapy
History of prior abdominal or pelvic radiotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify